OFS
ZNTL icon

OneAscent Financial Services’s Zentalis Pharmaceuticals ZNTL Stock Holding History

OneAscent Financial Services’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,427
Closed -$180K – 415
2024
Q1 		$180K Buy
11,427
+1,103
+11% +$15.2K 0.02% 371
2023
Q4 		$156K Buy
+10,324
New +$151K 0.02% 361

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

OneAscent Financial Services's ZNTL Position: Q2 2024 in Review

OneAscent Financial Services sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2024, closing a stake of 11,427 shares — an estimated $180K sold.

OneAscent Financial Services first reported a position in ZNTL in Q4 2023 and held it in 2 quarters. The position peaked at $180K in Q1 2024. 145 funds tracked by Wall St. Rank hold ZNTL as of Q2 2024.

  • OneAscent Financial Services reported no remaining Zentalis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • OneAscent Financial Services sold 11,427 Zentalis Pharmaceuticals shares in Q2 2024, an estimated $180K.
  • OneAscent Financial Services first reported a position in Zentalis Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • OneAscent Financial Services's Zentalis Pharmaceuticals position peaked at $180K in Q1 2024.
  • 145 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2024.

Based on OneAscent Financial Services's 13F filing for Q2 2024, filed 17 Jul 2024.